1. Amgen will present at Jefferies Global Healthcare Conference on June 4, 2025. 2. CFO Peter Griffith and EVP Murdo Gordon will lead the presentation. 3. The webcast will be accessible to media, investors, and the public. 4. Amgen focuses on innovative medicines for critical diseases. 5. In 2024, Amgen earned recognition as a top innovator and employer.
The conference highlights Amgen's commitment to innovation, potentially attracting investors and increasing stock value. Historical trends show that successful investor presentations often precede stock price increases.
The event showcases Amgen's leadership and innovation, which could enhance investor confidence and stock performance, given their substantial pipeline and recognition.
Immediate interest from investors can boost stock prices post-conference, similar results were observed after previous events.
PRNewswire -- Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:20 a.m. ET on Wednesday, June 4, 2025. Peter Griffith, executive vice president and chief financial officer at Amgen, and Murdo Gordon, executive vice president of Global Commercial Operations at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases.
In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.
For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn, Instagram, YouTube and Threads.
Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Justin Claeys, 805-313-9775 (investors)
SOURCE: Amgen